Forte Biosciences Q2 2023 Earnings Report $5.70 +0.14 (+2.52%) Closing price 04:00 PM EasternExtended Trading$5.70 +0.00 (+0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Forte Biosciences EPS ResultsActual EPS-$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AForte Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AForte Biosciences Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call DateMonday, August 14, 2023Conference Call Time7:00AM ETUpcoming EarningsForte Biosciences' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryFBRX ProfilePowered by Remove Ads Earnings DocumentsQuarterly report(10-Q) Forte Biosciences Earnings HeadlinesChardan Capital Expects Lower Earnings for Forte BiosciencesApril 8 at 2:23 AM | americanbankingnews.comBrookline Capital Management Predicts FBRX Q2 EarningsApril 8 at 1:37 AM | americanbankingnews.comThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 9, 2025 | Colonial Metals (Ad)Chardan Capital Cuts Forte Biosciences (NASDAQ:FBRX) Price Target to $61.00April 4, 2025 | americanbankingnews.comForte Biosciences price target lowered to $61 from $64 at ChardanApril 2, 2025 | markets.businessinsider.comIs Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?April 1, 2025 | finance.yahoo.comSee More Forte Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email. Email Address About Forte BiosciencesForte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.View Forte Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
